A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab

Prior treatment

• Previous treatment with immune checkpoint inhibitors;
• Received the following treatments or drugs before the first study treatment:
  • Major surgery within 28 days before treatment (tissue biopsy for diagnostic purposes is allowed).
  • Use of immunosuppressive drugs within 7 days before treatment, excluding nasal spray and inhaled corticosteroids or physiological doses of systemic steroid hormones (i.e. no more than 10 mg/d of prednisone or other corticosteroids of equivalent physiological dose);
  • Received immunomodulatory drugs (such as thymosin, interferon, interleukin) within 3 weeks before medication;
  • Received live attenuated vaccines within 28 days before treatment;
  • Received other anti-tumor systemic treatment within 28 days before treatment;
• Within 6 months before entering the study, the following conditions occurred: myocardial infarction, severe/unstable angina, NYHA Patients with grade 2 or above heart failure and clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention; hypertension that is poorly controlled by drugs;
• History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or active gastrointestinal bleeding within 6 months before the first study treatment;

Other illness

• Known allergy to the study drug or any of its excipients;
• Presence of any active autoimmune disease or history of autoimmune disease and expected recurrence;
• Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
• Human immunodeficiency virus (HIV) infection or known AIDS, untreated active hepatitis, HBV-DNA ≥ 2500 IU/ml and abnormal liver function; hepatitis C or co-infection with hepatitis B and hepatitis C;
• Unable to swallow the study drug, with multiple factors that affect drug administration and absorption, such as chronic diarrhea (including but not limited to irritable bowel syndrome, Crohn's disease, ulcerative colitis) and intestinal obstruction;

Lab values

• Patients with other serious physical or laboratory abnormalities that may increase the risk of participating in the study or interfere with the study results, and patients who are considered unsuitable for participation in this study by the investigator;

Other

• Urine protein ≥++ or 24-hour urine protein \> 1.0g;
• Pregnant or lactating women, and subjects with reproductive capacity who are unwilling to take effective contraceptive measures;

• Voluntary participation and written informed consent
• Aged 18 years and above, regardless of gender;
• Histologically confirmed, resectable primary lesions, unresectable metastatic lesions, MSS-type mCRC
• MCRIH by transcriptome typing;
• At least one measurable lesion diagnosed by imaging, according to the solid tumor response evaluation criteria (RECIST1.1);
• Estimated survival ≥ 3 months;
• ECOG score 0-1 points;
• Adequate organ and bone marrow function:
  • Neutrophil count: ≥1.5\*10\^9/L Platelet count: ≥10.0\*10\^9/L Hemoglobin: ≥ 9.0 g/dL Total bilirubin: ≤ 1.5 ULN AST, ALT: ≤ 2.5 \*ULN (or \<5\*ULN in case of liver metastasis) Serum creatinine: 1.25 \*ULN
• Male subjects and women of childbearing age must take contraceptive measures from the first dose to 3 months after the last dose;
• It is expected that the patient will have good compliance and can cooperate with the study as required by the protocol;